pharma news today glp-1 obesity Drugs Market Size to Hit USD 132.79 Bn by 2035 GLP-1 RAs gain popularity as

Screening of the title and abstracts of the included studies by extracting the results and assessing the validity of the studies were performed independently by two authors (SR and OA) to determine whether they were eligible or not

Nevertheless, it is crucial to consider the potential adverse effects of weight fluctuation after discontinuing these medications, particularly the increased risk of cardiovascular and all-cause mortality in patients with obesity or overweight

These trials should follow standardized dosing, objective endpoints, and rigorous safety protocols

Notably, an analysis of hepatic gene expression of MAFLD patients showed that the expression of FMO1 but not FMO3 increases in MAFLD ( Statements Author contributions XL and JH participated in drafting the manuscript

1 Protection Liposomes act like a natural shield, protecting delicate nutrients from being destroyed by stomach acid and enzymes